Ignite Creation Date:
2024-10-26 @ 3:42 PM
Last Modification Date:
2024-10-26 @ 3:42 PM
Study NCT ID:
NCT06643013
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-10-14
Brief Title:
Targeting 18kDa Translocator Protein TSPO to Improve Brain Endothelial Cell Function in Cerebral Small Vessel Disease
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Targeting 18kDa Translocator Protein TSPO to Improve Brain Endothelial Cell Function in Cerebral Small Vessel Disease
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In healthy people blood flow to particular areas in the brain increases when the area becomes more active This ensures that the brain gets enough blood at the right place and time In people with cerebral small vessel disease cSVD this process is disrupted and the increased blood flow in response to activity is decreased or absent Damage to the endothelial cells that form the inner lining of blood vessels is a key pathological process in cSVD The aim of this study is to find out whether endothelial cell function and blood flow in cSVD can be improved by altering the function of a protein called TSPO We will do this by using a drug called XBD173 which binds to TSPO
This is a double-blind randomised crossover study cSVD patients will be recruited from memory clinics at Imperial College Healthcare NHS Trust Participants will be invited to the clinical research facility CRF at Hammersmith Hospital and randomised to receive XBD173 or matched placebo twice daily for 4 weeks After a 6-week washout they will be switched to receive the other intervention The study visits will involve MRI scans and blood tests to assess endothelial cell function
Healthy volunteers will also be recruited for image optimisation and control data They will attend for a single MRI scan and not receive XBD173
This is a double-blind randomised crossover study cSVD patients will be recruited from memory clinics at Imperial College Healthcare NHS Trust Participants will be invited to the clinical research facility CRF at Hammersmith Hospital and randomised to receive XBD173 or matched placebo twice daily for 4 weeks After a 6-week washout they will be switched to receive the other intervention The study visits will involve MRI scans and blood tests to assess endothelial cell function
Healthy volunteers will also be recruited for image optimisation and control data They will attend for a single MRI scan and not receive XBD173
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None